- Home
- WRAP vs ABOS Comparison
WRAP vs ABOS Comparison
Compare WRAP & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRAP
- ABOS
- Stock Information
- Founded
- WRAP 2016
- ABOS 1996
- Country
- WRAP United States
- ABOS United States
- Employees
- WRAP N/A
- ABOS N/A
- Industry
- WRAP Ordnance And Accessories
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- WRAP Industrials
- ABOS Health Care
- Exchange
- WRAP Nasdaq
- ABOS Nasdaq
- Market Cap
- WRAP 91.2M
- ABOS 99.1M
- IPO Year
- WRAP N/A
- ABOS 2021
- Fundamental
- Price
- WRAP $2.00
- ABOS $1.63
- Analyst Decision
- WRAP
- ABOS Strong Buy
- Analyst Count
- WRAP 0
- ABOS 3
- Target Price
- WRAP N/A
- ABOS $9.33
- AVG Volume (30 Days)
- WRAP 313.3K
- ABOS 416.5K
- Earning Date
- WRAP 11-14-2024
- ABOS 11-12-2024
- Dividend Yield
- WRAP N/A
- ABOS N/A
- EPS Growth
- WRAP N/A
- ABOS N/A
- EPS
- WRAP N/A
- ABOS N/A
- Revenue
- WRAP $4,231,000.00
- ABOS N/A
- Revenue This Year
- WRAP N/A
- ABOS N/A
- Revenue Next Year
- WRAP N/A
- ABOS N/A
- P/E Ratio
- WRAP N/A
- ABOS N/A
- Revenue Growth
- WRAP N/A
- ABOS N/A
- 52 Week Low
- WRAP $1.21
- ABOS $1.53
- 52 Week High
- WRAP $7.01
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- WRAP 55.21
- ABOS 38.36
- Support Level
- WRAP $1.95
- ABOS $1.53
- Resistance Level
- WRAP $2.15
- ABOS $1.75
- Average True Range (ATR)
- WRAP 0.18
- ABOS 0.13
- MACD
- WRAP -0.01
- ABOS 0.01
- Stochastic Oscillator
- WRAP 56.90
- ABOS 23.81
About WRAP Wrap Technologies Inc.
Wrap Technologies Inc offers public safety technologies and services. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.